Biomerica, Inc. BMRA

Company Overview

Biomerica, Inc. is a U.S.-based biomedical technology and diagnostics company that develops, manufactures, and markets medical diagnostic products used for the detection and monitoring of chronic diseases and medical conditions. The company primarily operates within the in-vitro diagnostics (IVD) and healthcare diagnostics industries, with a focus on gastrointestinal diseases, food intolerance testing, diabetes monitoring, and infectious disease diagnostics. Its products are sold to hospitals, laboratories, physicians’ offices, clinics, and distributors in domestic and international markets.

The company’s primary revenue drivers include diagnostic test kits, point-of-care testing technologies, and laboratory-based assays. One of Biomerica’s most prominent development platforms is its gastrointestinal diagnostic portfolio, including products associated with celiac disease and irritable bowel syndrome (IBS). The company has also pursued commercialization opportunities around its InFoods® technology platform, designed to identify patient-specific foods associated with IBS symptoms. Founded in 1971 and headquartered in Irvine, California, Biomerica evolved from a diagnostic reagent manufacturer into a specialized developer of patented diagnostic technologies targeting underserved clinical markets.

Business Operations

Biomerica generates revenue through the sale of diagnostic products across several healthcare segments, including gastrointestinal diagnostics, food intolerance testing, diabetes screening, women’s health diagnostics, and infectious disease testing. Its operations include manufacturing, research and development, regulatory compliance, and commercialization activities. The company markets products under multiple brands and platforms, including InFoods® IBS, EZ Detect™, and various ELISA-based diagnostic assays. Revenue is derived from direct sales, distributor relationships, licensing arrangements, and international partnerships.

The company maintains both domestic and international operations, with product distribution spanning North America, Europe, Asia, the Middle East, and Latin America. Biomerica controls proprietary diagnostic technologies, patents, and manufacturing capabilities related to immunoassay and rapid diagnostic testing. Its operating structure includes wholly owned subsidiaries such as Biomerica de Mexico, which supports manufacturing and operational activities. The company has historically collaborated with laboratories, healthcare providers, and commercial distribution partners to expand market penetration and support product validation initiatives.

Strategic Position & Investments

Biomerica’s strategic direction has centered on expanding its proprietary gastrointestinal diagnostic portfolio and increasing adoption of personalized diagnostic solutions. A major focus has been the advancement of InFoods® IBS, which is designed to identify foods linked to IBS symptoms through patient-specific immune responses. The company has emphasized clinical validation studies, intellectual property expansion, and regulatory positioning to differentiate its offerings within the gastrointestinal diagnostics market.

The company has also invested in broader diagnostic capabilities through product development initiatives targeting diabetes management, colon disease screening, and rapid diagnostic applications. Biomerica’s strategy includes leveraging partnerships with distributors and laboratories to scale commercialization while maintaining internal research and manufacturing capabilities. Public filings and investor materials indicate continued investment in product innovation and regulatory approvals, although commercialization timelines and adoption rates for certain products remain subject to market acceptance and healthcare reimbursement dynamics.

Geographic Footprint

Biomerica is headquartered in Irvine, California, and maintains operational and manufacturing activities in both the United States and Mexico. The company sells products internationally through distributors and commercial partners across more than 70 countries, with meaningful presence in North America, Europe, Asia, the Middle East, and Latin America.

Its international reach is primarily driven by diagnostic kit distribution and laboratory partnerships rather than large-scale physical infrastructure abroad. The company’s manufacturing subsidiary in Mexico supports cost-efficient production and operational scalability. Biomerica’s global market presence reflects its strategy of targeting niche diagnostic categories with internationally distributable testing products and proprietary assay technologies.

Leadership & Governance

Biomerica’s leadership team has historically emphasized diagnostic innovation, intellectual property development, and expansion into personalized medicine applications. The company’s governance structure follows a traditional public-company framework, with executive management overseeing research, manufacturing, commercialization, regulatory affairs, and financial operations. Strategic messaging from leadership has consistently focused on expanding clinical adoption of proprietary gastrointestinal diagnostics and strengthening long-term shareholder value through product commercialization.

Key executives include:

• Zackary Irani – Chief Executive Officer
• Richard J. Dame – Chief Financial Officer
• Marlene Moore – Vice President of Quality Assurance and Regulatory Affairs
• Martha Sanchez – Vice President of Operations
• Jagpal Singh – Vice President of Research and Development

The company was founded by members of the Irani family, who have remained closely associated with leadership and strategic direction. Information regarding executive roles and governance has been consistently disclosed in SEC filings, annual reports, and company investor materials.